The Chemours Company $CC Stock: VIRGINIA RETIREMENT SYSTEMS ET Al Increases Position

VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in shares of The Chemours Company (NYSE:CC) by 853.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,200 shares of the specialty chemicals company’s stock after buying an additional 88,800 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Chemours were worth $1,346,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. acquired a new stake in Chemours in the second quarter worth about $34,000. Allworth Financial LP purchased a new stake in shares of Chemours during the second quarter worth about $51,000. State of Wyoming acquired a new position in shares of Chemours during the second quarter valued at about $67,000. Sterling Capital Management LLC increased its holdings in shares of Chemours by 839.3% during the third quarter. Sterling Capital Management LLC now owns 5,072 shares of the specialty chemicals company’s stock valued at $69,000 after acquiring an additional 4,532 shares in the last quarter. Finally, Nykredit A S acquired a new position in shares of Chemours during the second quarter valued at about $99,000. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Chemours

In other news, insider Calderon Gerardo Familiar purchased 1,935 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was purchased at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the transaction, the insider owned 58,547 shares of the company’s stock, valued at $909,234.91. This trade represents a 3.42% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Denise Dignam acquired 3,378 shares of Chemours stock in a transaction that occurred on Tuesday, August 11th. The stock was purchased at an average cost of $14.95 per share, with a total value of $50,501.10. Following the completion of the purchase, the chief executive officer owned 339,916 shares in the company, valued at $5,081,744.20. The trade was a 1.00% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 0.85% of the company’s stock.

Chemours Stock Up 5.1%

CC opened at $13.76 on Thursday. The company has a market cap of $2.07 billion, a PE ratio of -13.49 and a beta of 1.47. The Chemours Company has a twelve month low of $10.44 and a twelve month high of $28.67. The company has a 50-day moving average price of $14.08 and a 200 day moving average price of $18.25. The company has a quick ratio of 0.88, a current ratio of 1.81 and a debt-to-equity ratio of 24.25.

Chemours (NYSE:CC) last posted its quarterly earnings data on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.26 by ($0.05). Chemours had a positive return on equity of 76.52% and a negative net margin of 2.64%. The firm had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.53 billion. During the same quarter in the previous year, the firm posted $0.40 earnings per share. The company’s quarterly revenue was up 3.0% on a year-over-year basis. Sell-side analysts expect that The Chemours Company will post 0.83 earnings per share for the current fiscal year.

Chemours Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be given a $0.0875 dividend. This represents a $0.35 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Monday, November 16th. Chemours’s dividend payout ratio (DPR) is -34.31%.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched FaizEon two-phase liquid-cooling solutions for AI data centers, positioning the company to pursue demand from a fast-growing market. Article: Chemours launches FaizEon liquid-cooling solutions
• Positive Sentiment: Fourth-quarter 2026 revenue guidance of $1.7 billion–$1.8 billion is above the cited $1.4 billion consensus, offering a more favorable near-term sales outlook. Full-year revenue guidance of $5.9 billion was in line with consensus.
• Positive Sentiment: Truist maintained a Buy rating, though it lowered its price target to $18 from $20. Article: Truist price-target update
• Neutral Sentiment: UBS kept its Neutral rating but cut its target to $15 from $16, signaling limited conviction despite a target above the cited share price. Article: UBS adjusts Chemours price target
• Negative Sentiment: Third-quarter adjusted EPS of $0.21 missed the $0.26 consensus. Analyst commentary also cited weak volumes and a cautious fourth-quarter outlook, tempering the stronger revenue guidance. Article: Q3 results and outlook
• Negative Sentiment: Multiple law firms publicized a securities class action alleging Chemours misled investors about Opteon refrigerant aftermarket demand and distributor inventory. The claims are allegations, but the litigation may add uncertainty; the lead-plaintiff deadline is December 7, 2026. Article: Chemours class-action notice

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CC. JPMorgan Chase & Co. reduced their price target on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 13th. Morgan Stanley set a $18.00 price target on Chemours in a research report on Monday, August 10th. Zacks Research raised Chemours from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 10th. The Goldman Sachs Group reiterated a “neutral” rating and set a $16.00 target price on shares of Chemours in a research report on Friday, October 9th. Finally, Weiss Ratings cut shares of Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. Three investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $17.45.

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.